Thao Dang

Executive Director, Oncology Clinical Development Gilead Sciences

Seminars

Tuesday 13th October 2026
TROP2 ADC–Immunotherapy Combinations: Clinical Evidence, Emerging Strategies & Future Opportunities
6:15 pm
  • Contextualizing ADC combinations as the future of effective clinical approaches as more ADCs advance to standard of care oncology settings
  • Exploring ongoing work into Trodelvy-immunotherapy clinical combinations in breast, urothelial and lung cancers
  • Exploring rationale and strategy for novel combinations to maximize the therapeutic potential and patient impact of ADCs
Thao Dang